{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/glp-1-receptor-agonists/","result":{"pageContext":{"chapter":{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists","depth":2,"htmlHeader":"<!-- begin field 704ffbfc-1d20-4be7-b373-3407f3599366 --><h2>GLP-1 receptor agonists</h2><!-- end field 704ffbfc-1d20-4be7-b373-3407f3599366 -->","summary":"","htmlStringContent":"<!-- begin item 4a6a72c4-8403-4671-81f1-00df9ab9ed2a --><!-- end item 4a6a72c4-8403-4671-81f1-00df9ab9ed2a -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"83c6917d-18d3-5a14-bac3-4e88cbeb124a","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field 17d4f57e-14f5-4e60-93bc-d73bdb445ea3 --><h3>Recommended doses</h3><!-- end field 17d4f57e-14f5-4e60-93bc-d73bdb445ea3 -->","summary":"","htmlStringContent":"<!-- begin item 4b442541-f259-49b3-abb6-ec2db7c25293 --><!-- begin field 7e806f38-0202-4c04-b7c5-ec56ae961e7e --><p><strong>There are currently five GLP-1 receptor agonists available in the UK, which are</strong><strong> self-administered by subcutaneous injection </strong><strong>in the thigh, abdomen, or upper arm, rotating the injection sites from one injection to the next.</strong></p><ul><li><strong>The recommended doses are:</strong><ul><li>For exenatide:<ul><li>Standard-release formulation: 5 micrograms twice daily, increased if necessary, after at least 1 month to a maximum dose of 10 micrograms twice daily. It should be administered within 1 hour before two main meals (at least 6 hours apart). It should not be administered after a meal.</li><li>Modified-release formulation: 2 mg once weekly on the same day each week (at any time, with or without meals). The day of weekly administration can be changed if necessary, as long as the next dose is administered at least 24 hours later. </li></ul></li><li>For liraglutide:<ul><li>0.6 mg once daily, increased after at least 1 week to 1.2 mg once daily. This can be further increased if necessary, after an interval of at least 1 week to a maximum dose of 1.8 mg once daily.</li></ul></li><li>For lixisenatide:<ul><li>10 micrograms once daily for 14 days, to be taken within 1 hour before the first meal of the day or the evening meal, increased to 20 micrograms once daily thereafter.</li></ul></li><li>For dulaglutide:<ul><li>0.75 mg once weekly as monotherapy; 1.5 mg once weekly as add-on therapy.</li></ul></li><li>For semaglutide:<ul><li>0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks, then increased to 1 mg once weekly if needed.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 7e806f38-0202-4c04-b7c5-ec56ae961e7e --><!-- end item 4b442541-f259-49b3-abb6-ec2db7c25293 -->","subChapters":[]},{"id":"c93bef43-a264-56a3-8336-4cd83681b506","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 109bc581-8cea-4a3e-bb23-505885a7fbcf --><h3>Contraindications and cautions</h3><!-- end field 109bc581-8cea-4a3e-bb23-505885a7fbcf -->","summary":"","htmlStringContent":"<!-- begin item 0a27b9d8-4a36-44fc-88d8-1765d15ec76f --><!-- begin field 43493a71-d8db-4c4f-bc87-8f7ee6c2c2fc --><ul><li><strong>Do not prescribe a </strong><strong>GLP-1 receptor agonist to people with:</strong><ul><li>Ketoacidosis.</li><li>Pancreatitis.</li><li>Renal impairment:<ul><li>Avoid exenatide standard-release and liraglutide injection if estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m<sup>2</sup>.</li><li>Avoid exenatide modified-release injection if eGFR is less than 50 mL/min/1.73 m<sup>2</sup>.</li><li>Avoid liraglutide and semaglutide in end-stage renal disease.</li></ul></li><li>Severe hepatic impairment — avoid liraglutide.</li><li>Severe gastrointestinal disease — avoid exenatide, liraglutide (for example if diabetic gastroparesis or inflammatory bowel disease), lixisenatide, and dulaglutide.</li></ul></li><li><strong>Prescribe a GLP-1 receptor agonist with caution in:</strong><ul><li>People with a history of pancreatitis — discontinue if symptoms of acute pancreatitis occur.</li><li>People with renal impairment — if eGFR is 30–50 mL/min/1.73 m<sup>2</sup> use standard-release exenatide and lixisenatide with caution.</li><li>People with hepatic impairment — caution with semaglutide.</li><li>Elderly people — may cause weight loss (exenatide).</li><li>Women of childbearing potential — advise that effective contraception should be used:<ul><li>During treatment with exenatide or lixisenatide.</li><li>During treatment with modified-release exenatide injection, and continued for 12 weeks after discontinuation of treatment.</li></ul></li><li>People with severe heart failure — use liraglutide and semaglutide with caution.</li><li>People with thyroid disease — history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) type 2 disease (for liraglutide).</li><li>People with retinopathy — use semaglutide with caution.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Morris, 2020</a>]</p><!-- end field 43493a71-d8db-4c4f-bc87-8f7ee6c2c2fc --><!-- end item 0a27b9d8-4a36-44fc-88d8-1765d15ec76f -->","subChapters":[]},{"id":"881fa7d7-2add-5208-acae-3075a62a0911","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 362a5971-52a9-4015-84f5-9fe11a07a8ae --><h3>Adverse effects</h3><!-- end field 362a5971-52a9-4015-84f5-9fe11a07a8ae -->","summary":"","htmlStringContent":"<!-- begin item 52c4ea40-e595-4802-865d-b6cab63930d1 --><!-- begin field 7b9f20b8-eab7-4e2e-97ee-ae5dae6dc1ce --><p><strong>Possible adverse effects of GLP-1 receptor agonists include:</strong></p><ul><li>Acute pancreatitis (rare) — advise the person to seek urgent medical advice if symptoms such as severe upper abdominal pain, nausea, and/or vomiting develop. Advise to discontinue treatment if pancreatitis is suspected.</li><li>Gastrointestinal — decreased appetite, altered taste, nausea, vomiting, dyspepsia, burping, gastro-oesophageal reflux, constipation, diarrhoea, gallbladder disorders (liraglutide).</li><li>Headache, dizziness, drowsiness, alopecia, hyperhidrosis.</li><li>Renal impairment (exenatide, liraglutide).</li><li>Atrioventricular block, sinus tachycardia (dulaglutide).</li><li>Skin reactions including rash, angioedema, urticaria, and pruritus.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 7b9f20b8-eab7-4e2e-97ee-ae5dae6dc1ce --><!-- end item 52c4ea40-e595-4802-865d-b6cab63930d1 -->","subChapters":[]},{"id":"480c20a4-bfe1-5016-a8d5-fcc3c3301288","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0ec21641-5633-4831-ab5c-5a0d97e9ba24 --><h3>Drug interactions</h3><!-- end field 0ec21641-5633-4831-ab5c-5a0d97e9ba24 -->","summary":"","htmlStringContent":"<!-- begin item 3880b953-9ba8-4d3d-bfeb-59701b0b549b --><!-- begin field 62fa90b5-0d08-438b-973f-c58933a3d565 --><ul><li><strong>Possible drug interactions associated with GLP-1 receptor agonists include:</strong><ul><li>Beta-blockers — the warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment with a beta-blocker.</li><li>Paracetamol — lixisenatide possibly reduces the absorption of paracetamol when given 1–4 hours before paracetamol.</li><li>Warfarin — exenatide and liraglutide possibly enhance the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR) during concurrent treatment with warfarin. Also consider monitoring INR at the time of initiation or stopping of lixisenatide treatment.</li><li>Other orally administered drugs — may need to be taken at least 1 hour before or 4 hours after lixisenatide or exenatide injection or taken with a meal when lixisenatide is not administered, to minimize possible interference with absorption.</li><li>Other antidiabetic drugs — due to the increased risk of hypoglycaemia, the dose of concomitant sulfonylurea may need to be reduced.</li></ul></li><li><strong>In </strong><strong>addition:</strong><ul><li><strong>The blood glucose-lowering effects of GLP-1 receptor agonists may be enhanced by:</strong><ul><li>Alcohol.</li><li>Anabolic steroids.</li><li>Disopyramide.</li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Testosterone.</li></ul></li><li><strong>The blood glucose-lowering effects of GLP-1 receptor agonists may be</strong><strong> antagonized by:</strong><ul><li>Corticosteroids.</li><li>Diuretics (thiazide and related, and loop).</li><li>Oestrogens and progestogens.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 62fa90b5-0d08-438b-973f-c58933a3d565 --><!-- end item 3880b953-9ba8-4d3d-bfeb-59701b0b549b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}